OncoMatch/Clinical Trials/NCT05381103
PSMA-PET to Guide Prostatectomy
Is NCT05381103 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for prostate cancer.
In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason 3+4 with pattern 4 ≥20%Gleason 3+4 with ≥50% total involvement of core≥3 cores of Gleason 3+4Any Gleason 4+3, 4+4, 4+5, 5+4, or 5+5 (Gleason)
Significant prostate cancer: Gleason 3+4 ≥1 core with pattern 4 ≥20%; Gleason 3+4 ≥1 core with ≥50% total involvement of core OR ≥3 cores of Gleason 3+4 OR NCCN unfavorable intermediate risk OR Any Gleason 4+3, 4+4, 4+5, 5+4, or 5+5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine · Indianapolis, Indiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify